Issue link: http://osercommunicationsgroup.uberflip.com/i/562613
C h a i n D r u g s t o r e D a i l y M o n d a y, A u g u s t 2 4 , 2 0 1 5 5 8 AMNEAL CONTINUES TO EXPAND GENERIC MARKETPLACE Fulfilling its promise to provide top- quality, affordable medications, Amneal Pharmaceuticals will arm retail pharma- cy with an impressive cache of new prod- ucts. Amneal has committed extensive resources across all seven dosage forms to ensure each area of focus has the expertise, technology, equipment and support to deliver quality products. Each team of experts is dedicated exclusively to a particular product or category. This arrangement drives the quality-by-design approach towards the company's ulti- mate goal of successful commercial scale-up of approved products. To develop its small-molecule injectables portfolio, Amneal implement- ed major investments in R&D, product development, production capacity and technology in addition to strategic part- nerships and licensing agreements. Manufacturing plants feature state-of- the-art infrastructure with advanced fin- ished dose and API operations for both conventional and specialized processing. The injectables pipeline targets a range of therapeutic areas, including numerous first-to-market generics. General purpose and oncology injecta- bles will be available as solution or sus- pension vials, lyophilized vials, pre-filled syringes and self-injecting pens, while the Amneal portfolio also includes com- plex molecules such as synthetic/DNA peptides, microspheres, liposomal, pen/cartridge and other device-based products. Of Amneal's 130 ANDAs filed, injectables represent 14 of those plus an additional 53 injectables are under devel- opment, representing a combined U.S. market value of $21.4 billion with the first Amneal injectables expected to launch in 2016. One of only two generics manufac- turers to produce hydrogel transdermal patches in-house, Amneal began development of these products three years ago. After hiring a leading expert in this area, Amneal equipped him with the state-of-the-art equipment, facilities and sup- port team required to ensure success. The company has seven trans- dermal patch products in development using both hydrogel and matrix formats – a demonstration of Amneal's commit- ment to pursue the most challenging products in the market. First approved in Europe, biosimilars are a "generic-like" form of biologics such as antibodies and vaccines made from liv- ing organisms. In March, the FDA approved its first biosimilar – a milestone in reducing the high costs of specialty drugs for patients with complex illnesses, predicted to save millions of healthcare dollars. Seizing this opportunity to expand its considerable array of high-quality generics, Amneal has developed a biosim- ilars pipeline of four products aimed at a $15-plus billion U.S. market. What does this mean for retail phar- macy? Amneal will create new, differenti- ated medications enabling retail cus- tomers to be active players in this high- growth segment of specialty pharmacy. As the line between retail and specialty continues to blur, the company remains committed to engaging and supplying its retail customers with these in-demand products. Innovation and diversification, in keeping with the company's pledge to meet evolving customer needs, has made Amneal one of the world's fastest grow- ing generics suppliers and a recognized market leader. Through it all, the company's found- ing principles – the relentless pursuit of quality, customer value creation and the building of deep, trusting relationships – remain the foundation of its growth and continued success. To learn more about Amneal, visit booth #106 or go to www.amneal.com. NEW PAYMENT STANDARDS THAT CAN CHANGE YOUR BUSINESS By Jeff Ditges, President, Source Communications All that credit card fraud that's costing your drug store millions is about to get a kick in the pants. There are new payment technology standards that are poised to take over all card processing in the U.S., which will make your life easier in the long run, but there are a few critical things you should know. The U.S. is Switching to EMV Payments EMV, which stands for Europay, MasterCard and Visa, uses credit cards with a microchip. The microchip-enabled EMV card holds information unique to the user, allows for remote deactivation, and limits the capability of fraudsters to duplicate cards. The U.S. is the only major economy in the world that does not currently use EMV, (also known as integrated-circuit (IC) and PIN and Chip.) The majority of U.S. cards still rely on magnetic-stripe technology that is more than four decades old and inherently insecure. Making the shift to EMV is costly, but when you consider the massive secu- rity breaches – such as the 70 million customer cards hacked in the Target attack – it's a bargain. New Security Standards The U.S. is in the beginning stages of making this transition. The credit card brands Visa and MasterCard have volun- tarily enacted updated security standards to protect financial institutions, mer- chants and consumers alike. These stan- can face steep penalties, up to and including the loss of the ability to process credit cards. That would put many small drugstores and pharmacies out of business in short order. For national chains, the bad PR alone could bankrupt your business. Your Critical Next Steps 1. Be sure you understand the PCI DSS requirements and protect your business and your customers. 2. When you switch to the new EMV card readers, remember that the card reader is only as secure as the stand it rests on. 3. Visit Source Communications for pay- ment organization solutions and PCIDSS compliant card reader stands. Visit Source Communications at booth #156. dards, called the Payment Card Industry Data Security Standards (PCIDSS), ensure that anyone who processes credit cards is meeting the industry's best security prac- tices. Shift in Fraud Liability Here's the important part for pharma- cies and drugstores. After October 15th of this year, if a merchant has an inci- dence of card fraud, whichever party has the lesser technology will bear the liability. For example, if your drugstore is using the old system, you can still run a transaction with a swipe and a signature. However, you will be liable for any fraudulent transactions if the customer used an EMV-enabled card. Similarly, if the merchant has a new terminal, but the bank hasn't issued an EMV card to the customer, the bank is liable. If you're hacked and you were not compliant beforehand, your business